Neurocrine Biosciences
NBIX
649 hedge funds and large institutions have $13.6B invested in Neurocrine Biosciences in 2025 Q3 according to their latest regulatory filings, with 121 funds opening new positions, 220 increasing their positions, 219 reducing their positions, and 50 closing their positions.
142% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 50
11% more funds holding
Funds holding: 585 → 649 (+64)
10% more capital invested
Capital invested by funds: $12.4B → $13.6B (+$1.19B)
0% more repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 219
1.93% less ownership
Funds ownership: 99.95% → 98.01% (-1.9%)
31% less funds holding in top 10
Funds holding in top 10: 16 → 11 (-5)
51% less call options, than puts
Call options by funds: $33.1M | Put options by funds: $67.7M
Top Buyers
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$171M |
| 2 |
JP Morgan Chase
New York
|
+$63.5M |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
+$62.1M |
| 4 |
Two Sigma Investments
New York
|
+$47.1M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$38.8M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$170M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$84.3M |
| 3 |
Axa
Paris,
France
|
-$43M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$42.9M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$38M |
NBIX Hedge Fund Activity: Q3 2025 in Review
649 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2025, worth a combined $13.6B — up 9.6% from $12.4B a quarter earlier.
Buyers outnumbered sellers: 121 funds opened new NBIX positions and 50 closed out — a net gain of 71 holders — while 220 added to existing stakes and 219 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $171M. The largest seller was Citadel Advisors, cutting an estimated $170M.
- 649 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2025, up from 585 in Q2 2025.
- Funds reported $13.6B of Neurocrine Biosciences stock for Q3 2025, up 9.6% quarter-over-quarter.
- 121 funds opened new Neurocrine Biosciences positions in Q3 2025 and 50 closed out, a net change of +71 holders.
- The largest Neurocrine Biosciences buyer in Q3 2025 was AQR Capital Management, an estimated $171M added.
- The largest Neurocrine Biosciences seller in Q3 2025 was Citadel Advisors, an estimated $170M sold.
Based on aggregated 13F filings for Q3 2025.